Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AZN and ABBV both boast strong drug pipelines and growth outlooks, but differences in valuation, dividends and LOE risks set them apart.

Zacks Investment Research • 14 hours ago

AstraZeneca's Imfinzi with pre-surgery drug boosts survival in bladder cancer trial

AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with ​a targeted therapy prior to a ‌surgery, showed significantly improved survival rate in patients with muscle-invasive bladder cancer.

Reuters • May 14, 2026

Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement With AstraZeneca

NEW YORK & PARIS--(BUSINESS WIRE)--Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their three-year licensing of K Pro – Owkin's AI Scientist for biopharma decision making. K Pro brings multimodal data and specialized biological agentic AI to each step of the value chain. Under the three-year licensing agreement, Owkin will lead the.

Business Wire • May 13, 2026

BioInvent to Present Clinical Data on FcγRIIB Antibody BI-1206 Triplet Combination Therapy with rituximab and Calquence(R) in Relapsed/Refractory NHL at EHA 2026

LUND, SE / ACCESS Newswire / May 12, 2026 / BioInvent International (STO:BINV) - BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it has been selected for a poster presentation of the BI-1206 triplet combination in relapsed/refractory non-Hodgkin's lymphoma (NHL) at the 31st European Hematology Association (EHA2026) Congress, taking place June 11-14, 2026 in Stockholm, Sweden. Poster Presentation Title: Targeting resistance to rituximab through FcγRIIB (CD32B) blockade: BI-1206 + rituximab + acalabrutinib shows powerful activity in R/R NHL Presenter: Dr. Laura Fogliatto, Hospital de Clínicas de Porto Alegre, Brazil Session Date/Time: Friday, June 12, 6:45 pm-7:45 pm CEST (12:45 pm-1:45 pm EDT) Location: EHA2026 Congress, Stockholm The presentation will summarize emerging efficacy and safety observations and mechanistic insights from the ongoing Phase 1/2 study (NCT03571568) evaluating BI-1206 in combination with rituximab and Calquence® (acalabrutinib) in patients with relapsed or refractory NHL, including follicular lymphoma.

Accesswire • May 12, 2026

Polen International Growth Q1 2026 Portfolio Activity

In Q1 2026, Polen International Growth Portfolio returned -14.4% (net of fees) compared to -0.7% for the Index. We initiated new positions in TSMC, Rheinmetall, Saab, Mitsubishi Heavy Industries, AstraZeneca, AIA Group, Siemens Energy, Samsung Electronics, and Keyence. We sold our holdings in Nintendo, MakeMyTrip, Adidas, Globant, Amadeus IT Group, Monday.com, ICON plc, and HDFC Bank.

Seeking Alpha • May 10, 2026

6 Pharma Dividend Stocks Yielding Up to 6.44% — and They've Survived Every Market Crash

Dividend income arrives whether markets rally or sell off. For investors seeking recurring cash flow, high-yield equities remain the cleanest source outside a paycheck.

24/7 Wall Street • May 6, 2026

The Most Important Part of These 3 Big Pharma Earnings Reports Wasn't the Beat

Earnings season is in full swing, and on April 29, three Big Pharma mainstays reported Q1 2026 earnings. Investors were looking for strong results—and strong guidance—that could serve as a sorely needed tailwind for the healthcare sector.

MarketBeat • May 2, 2026

AstraZeneca's Breast-Cancer Candidate Drug Loses FDA Panel Vote

The British pharmaceutical group said it would continue to work with U.S. regulators on a review of its breast-cancer candidate after the drug failed to get backing at a key advisory committee vote.

WSJ • May 1, 2026

AstraZeneca stock falls after FDA panel votes against new cancer drug

An advisory panel for the U.S. Food and Drug Administration voted 6-3 against AstraZeneca's oral drug camizestrant intended for a type of breast cancer tumor, citing concerns around trial design. AstraZeneca's London-listed shares fell on the back of the vote outcome.

CNBC • May 1, 2026

AstraZeneca shares drop after US regulatory panel votes against breast cancer drug

Shares of ​AstraZeneca fell ‌1.7% on ​Friday ​after an advisory ⁠panel ​for the ​U.S. Food and ​Drug ​Administration overnight voted ‌against ⁠recommending the British drugmaker's ​experimental ​breast ⁠cancer ​treatment.

Reuters • May 1, 2026